By Scientia Professor Anthony D Kelleher

Journal articles

Kaufmann D; Kavanagh D; Pereyra F; Zaunders J; Mackey E; Miura T; Palmer S; Brockman M; Rathod A; Piechocka-Trocha A; Baker B; Zhu B; Le Gall S; Waring M; Ahern R; Moss K; Kelleher AD; Coffin J; Freeman G; Rosenberg E; Walker BD, 2007, 'Upregulation of CTLA-4 by HIV-specific CD4(+) T cells correlates with disease progression and defines a reversible immune dysfunction', Nature Immunology, 8, pp. 1246 - 1254

van Bockel D; Price DA; Asher TE; Venturi V; Suzuki K; Warton K; Davenport MP; Cooper DA; Douek DC; Kelleher AD, 2007, 'Validation of RNA-based molecular clonotype analysis for virus-specific CD8+ T-cells in formaldehyde-fixed specimens isolated from peripheral blood', Journal of Immunological Methods, 326, pp. 127 - 138, http://dx.doi.org/10.1016/j.jim.2007.07.016

Hemelaar J; Gouws E; Ghys PD; Osmanov S, 2006, 'Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004.', AIDS, 20, pp. W13 - W23, http://dx.doi.org/10.1097/01.aids.0000247564.73009.bc

Hales GP; Birch C; Crowe S; Workman C; Hoy JF; Kelleher AD; Lincoln D; Lincoln D; Law MG; Emery S, 2006, 'A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: The CREST study.', PLoS Clinical Trials, 1, pp. e18

Kelleher AD; Puls R; Bebbington M; Boyle D; Kent S; Kippax SC; Purcell D; Thomson S; Wand HC; Cooper DA; Emery S; Ffrench RA, 2006, 'A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1', AIDS, 20, pp. 294 - 297

Zaunders J; Dyer W; Munier CM; Ip S; Liu J; Amyes E; Rawlinson WD; Rose RJ; Kent SJ; Sullivan JS; Cooper DA; Kelleher AD, 2006, 'CD127+CCR5+CD38+++CD4+ Th1 Effector Cells Are an Early Component of the Primary Immune Response to Vaccinia Virus and Precede Development of Interleukin-2+ Memory CD4+ T Cells', Journal of Virology, 80, pp. 10151 - 10161

Kelleher AD; Zaunders J, 2006, 'Decimated or missing in action:CD4+ T cells as targets and effectors in the pathogenesis of primary HIV infection. Curr HIV/AIDS Rep 2006;3(1):5-12.', Current HIV/AIDS Reports, 3, pp. 5 - 12

De Rose R; Sullivan MT; Dale CJ; Kelleher AD; Emery S; Cooper DA; Ramshaw I; Boyle D; Kent SJ, 2006, 'Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines.', Human Vaccines, 2, pp. 134 - 136

Fazekos de St Groth B; Seddiki N; Santner-Nanan B; Martinson J; Zaunders J; Sasson SC; Landay A; Nanan R; Kelleher AD, 2006, 'Expression of IL-2 and IL-7 receptors discriminates between human regulatory and activated T-cells within CD45RA and CD45RO compartments', Clinical Immunology, 119, pp. S7 - S7

Seddiki N; Santner-Nanan B; Martinson J; Zaunders J; Sasson SC; Landay A; Solomon MJ; Selby W; Alexander S; Nanan R; Kelleher AD; Fazekas de St Groth B; Solomon M, 2006, 'Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells', Journal of Experimental Medicine, 203, pp. 1693 - 1700, http://dx.doi.org/10.1084/jem.20060468

Barbour J; Hecht FM; Little S; Markowitz M; Daar E; Kelleher AD; Routy J; Campbell T; Rosenberg E; Segal M; Weidler J; Grant R, 2006, 'Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity.', AIDS, 20, pp. 2123 - 2125

Sasson SC; Zaunders J; Zanetti G; King E; Merlin K; Smith DE; Stanley K; Cooper DA; Kelleher AD, 2006, 'Increased plasma interleukin-7 level correlates with decreased CD127 and increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infection', Journal of Infectious Diseases, 193, pp. 505 - 514

Zaunders J; Ip S; Munier CM; Munier M; Kaufmann D; Suzuki K; Brereton C; Seddiki N; Sasson SC; Koelsch KK; Landay A; Grey PA; Finlayson R; Kaldor JM; Rosenberg E; Walker BD; Fazekas de St Groth B; Cooper DA; Kelleher AD, 2006, 'Infection of CD127(+) (Interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection', Journal of Virology, 80, pp. 10162 - 10172

Carlin S; Moore JJ; Zaunders J; Kelleher AD; Ma DD, 2006, 'T lineage differentiation in vitro of adult Haematopoietic Stem Cells', CYTOMETRY PART A, 69A, pp. 399 - 400

Sasson SC; Zaunders J; Kelleher AD, 2006, 'The IL-7/IL-7 receptor axis: understanding its central role in T-cell homeostatis and the challenges facing its utilization as a novel therapy. 2006;7:1571-1582.', Current Drug Targets, 7, pp. 1571 - 1582

Bloch MT; Smith DE; Quan D; Kaldor JM; Zaunders J; Petoumenos K; Irvine K; Law MG; Grey PA; Finlayson R; Mcfarlane R; Kelleher AD; Carr AD; Cooper DA, 2006, 'The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: Final results from a randomized clinical trial (Pulse)', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 42, pp. 192 - 202

Ammaranond P; Zaunders J; Satchell C; Van Bockel DJ; Cooper DA; Kelleher AD, 2005, 'A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1', AIDS Research and Human Retroviruses, 21, pp. 395 - 397

Zaunders J; Munier M; Kaufmann D; Ip S; Grey PA; Smith DE; Ramacciotti TP; Quan D; Finlayson RJ; Kaldor JM; Rosenberg E; Walker BD; Cooper DA; Kelleher AD, 2005, 'Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection', Blood, 106, pp. 1660 - 1667

Sedwell R; Mallon PW; Duarte NL; Zaunders J; Kelleher AD; Cooper DA; Carr AD, 2005, 'Impaired mitochondrial function induced by NRTIs is only detectable in the monocyte (CD14(+)) subset of human PBMC', Antiviral Therapy, 10, pp. L44 - L45

Mallon PW; Unemori P; Sedwell R; Morey AL; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2005, 'In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA', Journal of Infectious Diseases, 191, pp. 1686 - 1696

Mallon PW; Sedwell R; Unemori P; Kelleher AD; Cooper DA; Carr AD, 2005, 'Methodological considerations in human studies of gene expression in HIV-associated lipodystrophy', Antiviral Therapy, 10, pp. M101 - M108

Lim H; Sedwell R; Duarte NL; Cooper DA; Kelleher AD; Carr AD; Mallon PW, 2005, 'Nucleoside reverse transcriptase inhibitor effects on adipocyte mitochondrial DNA quantity and quality in vitro', Antiviral Therapy, 10, pp. L41 - L42

Suzuki K; Shijuuku T; Fukamachi T; Zaunders J; Guillemin GJ; Cooper DA; Kelleher AD, 2005, 'Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region.', Journal of RNAi and Gene Silencing, 1, pp. 66 - 78

Emery S; Workman C; Puls R; Bloch M; Baker D; Bodsworth NJ; Anderson JA; Crowe SM; Hoy JF; Aichelburg A; Ward LA; Boyle D; Law MG; Kelleher AD; Cooper DA, 2005, 'Randomised, Placebo-Controlled, Phase 1/2a Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-y in HIV-1 Infected Subjects', Human Vaccines, 1, pp. 232 - 238, http://www.landesbioscience.com/journals/vaccines/emeryHV1-6.pdf

Sasson SC; Kelleher AD; Cooper DA, 2005, 'The modern ART of HIV infection management: Towards a tailored approach to maximize CD4 T cell reconstitution', Clinical Infectious Diseases, 41, pp. 373 - 375

Zaunders JJ; Dyer WB; Wang B; Munier ML; Miranda-Saksena M; Newton R; Moore J; Mackay CR; Cooper DA; Saksena NK; Kelleher AD, 2004, 'Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection', Blood, 103, pp. 2238 - 2247, http://dx.doi.org/10.1182/blood-2003-08-2765

Pett SL; Kelleher A, 2004, 'Antiretroviral therapy-induced immune restoration in HIV infection: A double-edged sword?', Expert Review of Anti Infective Therapy, 2, pp. 335 - 339, http://dx.doi.org/10.1586/14787210.2.3.335

Mallon PW; Sedwell R; Unemori P; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'Changes in nuclear gene expression resulting from NRTI-induced inhibition of mitochondrial transcription reveal links between mitochondrial dysfunction and lipid metabolism', Antiviral Therapy, 9, pp. L56 - L56

Furutsuki T; Hosoya N; Kawana-Tachikawa A; Tomizawa M; Odawara T; Goto M; Kitamura Y; Nakamura T; Kelleher AD; Cooper DA; Iwamoto A, 2004, 'Frequent transmission of Cytotoxic-T-Lymphocyte escape mutants of human immunodeficiency virus type 1 in the highly HLA-A24-positive Japanese population', Journal of Virology, 78, pp. 8437 - 8445

Zaunders J; Dyer W; Wang B; Munier M; Miranda-Saksena M; Newton R; Moore JJ; MacKay CR; Cooper DA; Saksena NK; Kelleher AD, 2004, 'Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term non-progressor and in CMV infection', Blood, 8, pp. 2765 - 2765

Mallon PW; Unemori P; Sedwell R; Morey AL; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'In vivo nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes independent to HIV infection', Antiviral Therapy, 9, pp. L11 - L11

Mallon PW; Sedwell R; Unemori P; Merlin K; McGinley C; Ammaranond P; Peperias M; Rafferty M; Williams KM; Samaras K; Morey AL; Chisholm DJ; Kelleher AD; Cooper DA; Carr AD, 2004, 'Nucleoside reverse transcriptase inhibitors (NRTI) decrease adipocyte and monocyte mitochondrial (mt) messenger RNA transcription in the absence of changes in mtDNA or cell morphology', Antiviral Therapy, 9, pp. L56 - L57

Lomas M; Liauw WS; Packham D; Williams KM; Kelleher AD; Zaunders J; Ward RL, 2004, 'Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy', Annals of Oncology, 15, pp. 324 - 329

Pett SL; Kelleher AD, 2003, 'Cytokine therapies in HIV-1 infection: Present and future', Expert Review of Anti Infective Therapy, 1, pp. 83 - 96, http://dx.doi.org/10.1586/14787210.1.1.83

Pett SL; Kelleher AD, 2003, 'Cytokine therapies in HIV-1 infection: present and future', Expert Review of Anti-Infective Therapy, 1, pp. 89 - 102

Wang B; Mikhail M; Dyer W; Zaunders J; Kelleher AD; Saksena N, 2003, 'First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection', Virology, 312, pp. 135 - 135

Murray JM; Kaufmann GR; Hodgkin PD; Lewin SR; Kelleher AD; Davenport MP; Zaunders JJ, 2003, 'Naive T cells maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty', Immunology and Cell Biology, 81, pp. 487 - 495

Ammaranond P; Cunningham PH; Oelrichs RB; Suzuki K; Harris C; Leas L; Grulich AE; Cooper DA; Kelleher AD; Harris C, 2003, 'No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001', AIDS, 17, pp. 264 - 267

Zaunders J; Moutouh-de Parseval L; Kitada S; Reed JC; Rought S; Genini D; Leoni L; Kelleher AD; Cooper DA; Smith DE; Grey PA; Estaquier J; Little S; Richman DD; Corbeil J, 2003, 'Polyclonal proliferation and apoptosis of CCR5+ T Lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2', Journal of Infectious Diseases, 187, pp. 1735 - 1735

Ammaranond P; Cunningham PH; Oelrichs RB; Suzuki K; Harris C; Leas L; Grulich AE; Cooper DA; Kelleher AD; Harris C, 2003, 'Rates of transmission of antiretroviral drug resistant strains of HIV-1', Journal of Clinical Virology, 26, pp. 153 - 153

Allen TM; Kelleher AD; Zaunders J; Walker BD, 2002, 'Structured treatment interruption and beyond', BIOFUTUR, pp. 52 - 58, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000180098300009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Allen TM; Kelleher AD; Zaunders J; Walker BD, 2002, 'Supervised or structured treatment interruption (STI) and beyond...', Biofutur, pp. 52 - 58

Appay V; Zaunders J; Papagno L; Sutton J; Jaramillo AB; Waters A; Eastbrook P; Grey PA; Smith DE; Mcmichael AJ; Cooper DA; Rowland-Jones SL; Kelleher AD, 2002, 'Characterization of CD4(+) CTLs ex vivo', Journal of Immunology, 168, pp. 5954 - 5958

Wang B; Dyer W; Zaunders J; Mikhail M; Sullivan JS; Haddad DM; Williams LA; Harris G; Holt J; Cooper DA; Miranda-Saksena M; Boadle R; Kelleher AD; Saksena NK, 2002, 'Comprehensive analyses of a unique HIV-1-infected nonprogressor reveal a complex association of immunobiological mechanisms in the context of replication-incompetent infection', Virology, 304, pp. 246 - 264

Kelleher AD; Sewell WA; Price DM, 2002, 'Dyslipidemia due to retroviral protease inhibitors', Nature Medicine, 8, pp. 308 - 308, http://dx.doi.org/10.1038/nm0402-308a

Cunliffe S; Wyer JR; Sutton J; Lucas M; Harcourt G; Klenerman P; Mcmichael AJ; Kelleher AD, 2002, 'Optimization of peptide linker length in production of MHC Class II/peptide tetrameric complexes increases yield, stability and allows identification of antigen specific CD4+ T cells in PBMC', European Journal of Immunology, 32, pp. 3366 - 3375

Allen TM; Kelleher AD; Zaunders J; Walker BD, 2002, 'STI and beyond: the prospects of boosting anti-HIV immune responses', Trends in Immunology, 23, pp. 456 - 460

Kelleher AD; Booth JL; Sewell AK; Oxenius A; Cerundolo V; McMichael AJ; Phillips RE; Price DA, 2001, 'Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes', AIDS Research and Human Retroviruses, 17, pp. 1063 - 1066, http://dx.doi.org/10.1089/088922201300343744

Kelleher AD; Long C; Holmes EC; Allen RL; Wilson J; Conlon C; Workman C; Shaunak S; Olson K; Goulder P; Brander C; Ogg G; Sullivan JS; Dyer W; Jones I; McMichael AJ; Rowland-Jones S; Phillips RE, 2001, 'Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses', Journal of Experimental Medicine, 193, pp. 375 - 385, http://dx.doi.org/10.1084/jem.193.3.375

Suzuki K; Cunningham P; Harris C; Leas L; Zaunders J; Cooper DA; Kaufmann GR; Pett SL; Kelleher A; Mukaide M; Imai M; Kondo M; Finlayson R, 2001, 'Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine', AIDS Research and Human Retroviruses, 17, pp. 1293 - 1296, http://dx.doi.org/10.1089/088922201750461366

Back to profile page